Developed and manufactured in accordance with international standards using Enzymatic technology, Imexpharm’s antibiotics not only enhance treatment effectiveness but also play a significant role in combating the growing issue of antimicrobial resistance in Vietnam.
The essential role of next-generation antibiotics in modern medicine
Antibiotics are among the most important achievements of modern medicine, playing a crucial role in the treatment of bacterial infections. From common conditions such as sore throat and pneumonia to severe cases like sepsis and meningitis, antibiotics help eliminate or inhibit bacteria, saving millions of lives each year.
However, antibiotics should only be used when bacterial infections are confirmed and must follow proper medical prescriptions. Misuse, incorrect dosage, or self-medication can reduce treatment effectiveness and contribute to antimicrobial resistance, a serious global health threat. The World Health Organization (WHO) has warned that antibiotic misuse could lead to up to 10 million deaths annually by 2050.
Imexpharm – A pioneer in high-quality antibiotic manufacturing
With nearly half a century dedicated to improving community health, Imexpharm is proud to be one of the largest antibiotic manufacturers and distributors in Vietnam. Since introducing Amoxicillin in 1980, the company has continuously innovated and diversified its product portfolio to meet various patient needs.
Currently, Imexpharm operates 12 EU-GMP-certified production lines across three manufacturing complexes (IMP2, IMP3, IMP4), the highest number in Vietnam’s pharmaceutical industry. This strong manufacturing foundation enables the company to supply a comprehensive range of leading antibiotics, particularly next-generation products widely used in treating respiratory infections when clinically indicated.
Broad-spectrum antibiotic portfolio
Imexpharm offers a diverse range of broad-spectrum antibiotics to treat infections from mild to severe. These include: Beta-lactams (Penicillins, Cephalosporins) for respiratory, urinary, and skin infections; Macrolides for patients allergic to Penicillin; Fluoroquinolones for severe infections; Tetracyclines and other groups for eye, skin, urinary infections and sexually transmitted diseases.
All products are manufactured using Enzymatic technology, which minimizes the use of solvents and chemicals compared to traditional methods. This results in higher purity, stability, improved patient safety, and reduced environmental impact.
Imexpharm antibiotics work by killing or inhibiting bacteria through various mechanisms, such as disrupting cell walls, inhibiting protein synthesis, or interfering with DNA replication. Proper use—following medical advice, correct dosage, and full treatment duration—is essential to avoid side effects and resistance.
Commitment to quality and community health
As a leading pharmaceutical company, Imexpharm possesses a strong R&D team and continuously applies advanced technologies in manufacturing. Its products meet international quality standards while remaining cost-effective and widely used in major hospitals through transparent tendering and distribution systems.
.jpg)
Guided by the mission of “Health for the Community,” Imexpharm remains committed to sustainable development. Strong trust from healthcare professionals and distribution networks has supported robust business growth, with Q2 2025 revenue increasing by 32% year-on-year and pre-tax profit rising by 38%.
Imexpharm continues to reinforce its leading position in Vietnam’s antibiotic sector through internationally standardized products and a sustainable development strategy. The company also collaborates with the medical community to organize annual “Sustainable Antibiotics” workshops, aiming to update clinical knowledge, share optimal treatment solutions, and promote responsible antibiotic use